Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients

International Immunopharmacology

Volumn 8, Issue 5, 2008, Pages 769-773

  Böhler, Torsten ^a   Canivet, Cindy ^a   Galvani, Sylvain ^a   Therville, Nicole ^a   Salvayre, Robert ^a   Negre Salvayre, Anne ^a   Durand, Dominique ^b   Thomsen, Mogens ^a   Rostaing, Lionel ^b   Kamar, Nassim ^a,b  

^a INSERM   (France)

^b CHU RANGUEIL   (France)

Author keywords

Enteric coated mycophenolate sodium; Kidney transplantation; Mycophenolate mofetil; Mycophenolic acid; Pharmacodynamics; Therapeutic drug monitoring

Indexed keywords

CD19 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD71 ANTIGEN; CD8 ANTIGEN; CYCLINE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CELL COUNT; CLINICAL ARTICLE; DRUG EFFECT; DRUG MONITORING; ENTERIC COATED TABLET; FLOW CYTOMETRY; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MAINTENANCE THERAPY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; CYTOKINES; DRUG MONITORING; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; T-LYMPHOCYTES; TABLETS, ENTERIC-COATED; TACROLIMUS;

EID: 41349118284     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.01.023     Document Type: Article

References (21)

1. Morris R.E., Hoyt E.G., Eugui E.M., and Allison A.C. Transplantation and its immunology. Prolongation of rat heart allograft survival by RS-61443. Surg Forum 7 (1989) 337-338
2. Sollinger H.W., Eugui E.M., and Allison A.C. RS-61443: mechanism of action, experimental and early clinical results. Clin Transplant 5 (1991) 523-526
3. Sollinger H.W. Update on preclinical and clinical experience with mycophenolate mofetil. Transplant Proc 28 (1996) 24-29
4. Halloran P.F. Molecular mechanisms of new immunosuppressants. Clin Transplant 10 (1996) 118-123
5. Morris R.E., Hoyt E.G., Murphy M.P., Eugui E.M., and Allison A.C. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 22 (1990) 1659-1662
6. Bullingham R., Monroe S., Nicholls A., and Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single dose oral and intravenous administration. J Clin Pharmacol 36 (1996) 315-324
7. Bullingham R.E., Nicholls A.J., and Kamm B.R. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34 (1998) 429-455
8. Barten M.J., Shipkova M., Bartsch P., Dhein S., Streit F., Tarnok A., et al. Mycophenolic acid interaction with cyclosporine and tacrolimus in vitro and in vivo: evaluation of additive effects on rat blood lymphocyte function. Ther Drug Monit 27 (2005) 123-131
9. Hesselink D.A., van Hest R.M., Mathot R.A., Bonthuis F., Weimar W., de Bruin R.W., et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 5 (2005) 987-994
10. Sollinger H.W. Mycophenolates in transplantation. Clin Transplant 18 (2004) 485-492
11. Kamar N., Oufroukhi L., Sallusto F., Cointault O., Lavayssiere L., Mouzin M., et al. Impact of mycophenolic acid dose modifications on renal function after kidney transplantation. Exp Clin Transplant 4 (2006) 510-517
12. Kamar N., Oufroukhi L., Faure P., Ribes D., Cointault O., Lavayssiere L., et al. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium. Nephrol Dial Transplant 20 (2005) 2231-2236
13. Oellerich M., and Armstrong V.W. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments. Ther Drug Monit 28 (2006) 720-725
14. Rostaing L., Mourad G., Kamar N., et al., French Myriade FR01 Study Group. Tolerability of enteric-coated mycophenolate sodium to 1 year in combination with cyclosporine and corticosteroids in renal transplant recipients. Transplant Proc 38 (2006) 2860-2863
15. Arns W., Breuer S., Choudhury S., Taccard G., Lee J., Binder V., et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 19 (2005) 199-206
16. Budde K., Glander P., Krämer B.K., Fischer W., Hoffmann U., Bauer S., et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation 83 (2007) 417-424
17. Böhler T., Nolting J., Kamar N., Gurragchaa P., Reisener K., Glander P., et al. Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. Ther Drug Monit 29 (2007) 77-86
18. van Gelder T., Klupp J., Barten M.J., Christians U., and Morris R.E. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 23 (2001) 119-128
19. Czock D., Rasche F.M., Carius A., Glander P., Budde K., Bauer S., et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis. J Clin Pharmacol 47 (2007) 850-859
20. Kamar N., Glander P., Nolting J., Bohler T., Hambach P., Liefeldt L., et al. Effect of mycophenolate mofetil monotherapy on T-cell functions and inosine monophosphate dehydrogenase activity in patients undergoing a kidney transplantation. Transplant Proc 38 (2006) 2292-2294
21. Barten M.J., van Gelder T., Gummert J.F., Boeke K., Shorthouse R., Billingham M.E., et al. Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection. Am J Transplant 2 (2002) 719-732